U.S. News Room - Daiichi Sankyo US
WEB3 days ago · Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Daiichi Sankyo and MSD’s ADC improves progression-free …
WEB1 day ago · MRK. Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC …
WEB1 day ago · Daiichi Sankyo's (DSNKY) ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid ...
WEB3 days ago · Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of its investigational antibody-drug conjugate (ADC) DS-9606 for...
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two …
WEB2 days ago · Merck and Daiichi Sankyo on Tuesday announced that their investigational antibody-drug conjugate patritumab deruxtecan hit the primary endpoint in the Phase III HERTHENA-Lung02 study in non-small cell lung cancer.
Daiichi (4568 JP) Sets Sights on Next Generation of Targeted …
WEB3 days ago · The Japanese cancer drug powerhouse Daiichi Sankyo Co. has its sights on the next generation of targeted oncology drugs, and this time it might not need a partner to get it over the line.
What can we help you find? - Merck
WEB2 days ago · Daiichi Sankyo and Merck’s patritumab deruxtecan demonstrates a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatment. Discussions with global regulatory authorities to be initiated.
Daiichi Sankyo Highlights Progress in Creating New Standards of …
WEBBASKING RIDGE, N.J., May 21, 2024 -- (BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 45 abstracts in multiple...
U.S. News Room - Daiichi Sankyo US
WEBFebruary 19, 2024. Application based on results from the TROPION-Lung01 phase 3 trial. If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate for patients with lung cancer.
Daiichi Sankyo and Merck Announce Global Development and ...
WEBOct 19, 2023 · Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R ...